Wednesday, January 28, 2026 1/28/2026

HCMV GPCR functions during latency and reactivation

Award Number: R01AI153348
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/18/2021
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

HCMV GPCR functions during latency and reactivation - Human cytomegalovirus (HCMV) is a wide-spread pathogen, infecting the majority of the population in the United States. This virus poses a significant threat to developing fetuses as well as to children and adults who lack a competent immune system, often causing severe disease and mortality. Once individuals acquire an HCMV infection, the virus remains with the host for life, in a latent or quiescent state in the hematopoietic compartment. During times of severe immunological stress, the virus reactivates to its active state, allowing for dissemination and subsequent disease. With the exception of the immuno-naïve and sero-negative organ transplant recipients, primary infection with HCMV rarely causes disease, but rather it is reactivation that leads to significant complications. Thus, to prevent HCMV-associated disease, we must gain a complete understanding of viral latency and reactivation. During latency, HCMV encodes three of the four viral G protein-coupled receptors (vGPCRs): US28, UL33, and UL78. We previously showed US28-mediated signaling is required for establishing and maintaining latency and modulates the expression of specific cellular targets that regulate the Major Immediate Early (MIE) locus, a master regulator in the latent-to-lytic switch. Our findings also reveal a requirement for UL33 and UL78 for efficient viral reactivation from latency. Therefore, we hypothesize the vGPCRs modulate specific host signaling pathways to regulate the balance between latency and reactivation. To explore this hypothesis, we will take advantage of novel approaches coupled with our arsenal of viral recombinants, as well as both in vitro and ex vivo latency model systems. In Aim 1, we will define mechanisms underlying US28-mediated signaling and how this impacts the recruitment of silencing factors to the MIE locus during latency. In Aim 2, we will determine how UL33 signaling impacts the transactivation of the MIE locus and subsequent reactivation, as well as delineate how the interaction between US28 and UL78 tips the balance from latent-to-lytic replication. In sum, the experiments proposed herein will lead to a greater understanding of the vGPCRs’ biological functions during latency and reactivation, laying the foundation for future studies to develop novel therapeutics to prevent HCMV reactivation and disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	5	1/20/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $422,768 )
2025	2025	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	5	3/6/2025	NON-COMPETING CONTINUATION	$422,768
														Subtotal = $422,768

Issue Date FY: 2024 ( Subtotal = $435,844 )
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	001	4	6/6/2024	NON-COMPETING CONTINUATION	$43,584
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	4	2/7/2024	NON-COMPETING CONTINUATION	$392,260
														Subtotal = $435,844

Issue Date FY: 2023 ( Subtotal = $435,844 )
2023	2023	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	3	1/13/2023	NON-COMPETING CONTINUATION	$435,844
														Subtotal = $435,844

Issue Date FY: 2022 ( Subtotal = $435,844 )
2022	2022	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	2	2/15/2022	NON-COMPETING CONTINUATION	$435,844
														Subtotal = $435,844

Issue Date FY: 2021 ( Subtotal = $437,753 )
2021	2021	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Allergy and Infectious Diseases Research	000	1	3/18/2021	NEW	$437,753
														Subtotal = $437,753

Grand Total All Awards = $2,168,053

Top

All Categories

About

Search

Reports

Data Submission

Award Information

HCMV GPCR functions during latency and reactivation

Award Number: R01AI153348

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/18/2021

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer